Immuneering Q3 2026 Earnings Date & Estimates

Immuneering (NASDAQ:IMRX) is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.

Immuneering’s lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance. The candidate has been evaluated in clinical studies for advanced solid tumors, including pancreatic ductal adenocarcinoma and other cancers driven by RAS pathway alterations. The company is also advancing additional research programs aimed at developing targeted therapies for oncology indications.

Founded in 2008 and headquartered in Cambridge, Massachusetts, Immuneering has built its operations around combining computational approaches with experimental drug development. The company’s leadership includes co-founder and Chief Executive Officer Benjamin Zeskind, who has helped guide its transition from a technology-focused discovery company into a clinical-stage drug developer. Immuneering’s work is primarily directed toward patients with advanced cancers in the United States and other regions where its clinical studies are conducted.